Restoring the natural shape of life through RNA therapeutics
Location: United States, Washington, Seattle
Total raised: $147.5M
Investors 4
| Date | Name | Website |
| - | New Enterp... | nea.com |
| - | Mission Bi... | missionbio... |
| - | Breton Cap... | bretoncapi... |
| - | Refactor C... | refactor.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.07.2021 | Series B | $112M | - |
| 08.11.2019 | Series A | $35.5M | New Enterp... |
Mentions in press and media 15
| Date | Title | Description |
| 10.04.2026 | Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development | Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies SUZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Vivatides Therapeutics, a global biotechnology company focused on developing ext... |
| 07.04.2022 | Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics | - Funding from long-term investors to build leading delivery platform and scalable drug discovery engine to enable modular and programmable medicines - Company is harnessing the potential of RNA therapeutics to deliver medicines to liver an... |
| 16.07.2021 | Shape Therapeutics picks up $112M | Shape Therapeutics has raised $112 million in a Series B co-led by Decheng Capital and Breton Capital. The Seattle-based company is a developer of RNA targeting, editing and replacement technologies intended to treat neurodegenerative disor... |
| 16.07.2021 | The continued divvying up of the Weinstein Company | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbofx. Paid Content How one health care company stays true to its mission From Viatris The film shop th... |
| 16.07.2021 | The continued divvying up of the Weinstein Company | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbofx. Paid Content 5 ways to build trust at your company—and why it matters From PwC The film shop tha... |
| 15.07.2021 | Shape builds out RNA editing tech with a major $112M funding boost | Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. RELATED: Prime Medicine uncloaks with $315M to push 'search and replace... |
| 15.07.2021 | Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapy | SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round... |
| 08.11.2019 | Shape Therapeutics raises $35.5M Series A round to develop RNA-based gene editing technology | The company describes its technology, RNAfix, as allowing for direct in vivo targeting and modification of RNA by using engineered adeno-associated viruses, suppressor tRNAs and proteins like adenosine deaminases acting on RNA, or ADARs. Sh... |
| 06.11.2019 | NEA Leads $35.5M Series A for Shape Therapeutics | SEATTLE--(BUSINESS WIRE)--Shape Therapeutics, Inc. (ShapeTx), a development-stage biotechnology company leading the field of RNA-editing gene therapy, announces $35.5M in Series A financing, led by New Enterprise Associates (NEA), with addi... |
| 06.11.2019 | Shape Therapeutics Raises $35.5M in Series A Financing | Shape Therapeutics, Inc., a Seattle, WA-based development-stage biotechnology company focused on RNA-editing gene therapy, raised $35.5M in Series A financing. The round was led by New Enterprise Associates (NEA), with participation from Cu... |
Show more